Itamar Medical
Last updated: Jul 31, 2026
Itamar Medical, now marketed as ZOLL Itamar, develops WatchPAT home sleep apnea tests and the CloudPAT digital workflow around peripheral arterial tonometry, oximetry, actigraphy, and related physiologic signals. It is an acquired medtech asset within ZOLL Medical, not an independent venture-backed startup.
Visit WebsiteCompany Overview
Itamar Medical's core product is WatchPAT, a wrist-worn home sleep apnea test that uses peripheral arterial tonometry (PAT) together with pulse rate, oximetry, actigraphy, body position, and related channels to support assessment of sleep-disordered breathing. The value proposition is not simply a smaller polysomnography device: the system is designed as a deployable clinical workflow in which a patient completes a study at home, data are uploaded, and a clinician receives an interpreted report. The current ZOLL Itamar portfolio includes WatchPAT ONE, WatchPAT 300, and the newer WatchPAT 400, while CloudPAT provides secure transfer and study interpretation. The company website also describes SleePATh and arrhythmia-related features, indicating an effort to connect sleep testing with broader digital and cardio-sleep workflows rather than relying on a single hardware SKU.
The market problem is large and operationally concrete. Obstructive sleep apnea is common and frequently undiagnosed, while laboratory polysomnography is capacity-constrained, expensive, and inconvenient for many patients. Home sleep apnea testing can expand access, shorten scheduling bottlenecks, and let sleep, primary-care, dental, and cardiology practices serve distributed patient populations. Itamar's commercial model therefore depends on clinical acceptance, appropriate patient selection, reimbursement, report quality, and integration into provider workflows. The official site describes WatchPAT Direct and related services that can handle shipping, patient education, study upload, and interpretation support; these services can reduce clinic friction but also add operational and compliance dependencies beyond the sensor itself.
Its competitive position is strongest where regulated evidence, ease of use, and a recognizable care pathway matter. PAT-based inference differentiates WatchPAT from respiratory-channel home tests, although clinicians may still compare it with conventional polysomnography and lower-cost alternatives. ResMed, Nox Medical, Compumedics, Philips Respironics, Somnoware, and consumer wearable platforms represent a mixture of direct competitors, workflow substitutes, and adjacent technologies. A durable advantage requires continued regulatory clearance, clinical validation, reliable signal quality across patient populations, strong reimbursement support, and dependable software security. The business is commercially mature, but the moat is not absolute: home-testing hardware can commoditize, guidelines and payer rules can change, and consumer devices can shape expectations even when they do not provide equivalent diagnostic evidence.
ZOLL completed its acquisition of Itamar Medical in December 2021, and the official release states that Itamar would operate as a ZOLL business division while principal operations in Caesarea continued. That ownership change is strategically meaningful: ZOLL can provide a larger medical-device sales, service, and critical-care infrastructure, but Itamar no longer offers standalone public equity exposure or an independent startup financing story. Current ZOLL careers material still identifies Caesarea as a main office and describes Israeli corporate, research-and-development, and manufacturing activity, while LinkedIn lists the division in the 201–500 employee band. These are useful traction and continuity signals, but they do not substitute for current segment revenue, margin, retention, utilization, or product-level market-share diligence.
The national-security case is plausible but bounded. A portable, low-burden physiologic measurement and remote interpretation stack could support occupational-health screening, fatigue-risk programs, deployment medical evaluation, or readiness research where repeated measurements are preferable to routine laboratory visits. However, the public evidence reviewed here establishes a sleep-medicine business, not a defense program, military contract, or validated operational-readiness product. PAT-derived sleep and autonomic signals should not be treated as a direct measure of alertness, stress, or mission performance without population-specific validation. For strategic readers, Itamar is best understood as a reference asset for regulated remote physiology and distributed diagnostics, with possible defense adjacency rather than defense-native differentiation.
Dual-Use Assessment
The underlying wearable physiology and remote-diagnostics capabilities have credible but unproven adjacency to occupational health, fatigue-risk management, and military readiness screening. Public evidence supports a regulated sleep-medicine business, not a defense product or government deployment, so the dual-use case should be treated as an application hypothesis requiring operational validation.
Strategic Fit Assessment
Itamar Medical is not a standalone direct diligence target because ZOLL completed its acquisition in 2021 and the former public company was delisted. The asset may still matter for strategic benchmarking, partnership diligence, or evaluation of adjacent remote-physiology companies, but the public record reviewed does not establish a separate current financing opportunity, growth rate, profitability profile, or defense contract. Any corporate-level diligence should be directed to ZOLL and Asahi Kasei rather than treating Itamar as an independent startup.
Strategic Value to U.S.-Israel Alliance
The asset has strategic value as an Israeli-originated, commercially deployed example of regulated wearable diagnostics moving from sensor hardware into a cloud-mediated clinical service. Its strongest relevance is to remote care, distributed diagnostics, cardio-sleep pathways, and occupational health. For security or defense planning, it is a technology reference and possible platform component; there is no public evidence here of military procurement, classified use, or validation of WatchPAT as a standalone readiness instrument.
Key Technologies
- Peripheral arterial tonometry sensing
- Wrist-worn home sleep apnea testing
- Pulse oximetry and heart-rate measurement
- Actigraphy, body-position, snoring, and chest-motion sensing
- PAT-based sleep and autonomic-signal analysis
- CloudPAT secure data transfer and study interpretation
- SleePATh digital sleep-care workflow
Use Cases & Applications
- At-home obstructive sleep apnea testing
- Sleep-clinic and primary-care diagnostic triage
- Cardiology-linked cardio-sleep screening
- Remote patient education, kit logistics, and study interpretation
- Occupational-health screening for safety-critical workforces
- Fatigue and sleep-readiness research in military or emergency-service populations
- Distributed monitoring programs where laboratory polysomnography is impractical
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile. The editorial policy explains how profiles are researched, where automated drafting is used, and how corrections work.
This record lists 5 public references used for company identity, status, positioning, or material-claim review.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- ZOLL Itamar company profile Official profile confirms the 1997 founding date, ZOLL division status, WatchPAT focus, and 2021 acquisition.
- ZOLL announcement closing acquisition of Itamar Medical Official acquisition release confirms the December 2021 closing, ZOLL ownership, Caesarea operations, and delisting context.
- ZOLL Itamar official website Official product pages describe WatchPAT, CloudPAT security certifications, WatchPAT 400, and the current ZOLL Itamar brand.
- ZOLL Itamar careers Official careers page identifies main offices in Caesarea, Atlanta, and Amsterdam and describes current division activity.
- ZOLL Itamar on LinkedIn Current company profile lists 201-500 employees, a 1997 founding year, and Caesarea as an operating location.
- Profile update timestamp Last updated in the Claw & Talon database on Jul 31, 2026.
Investor Lens
What this entry is
Acquired asset
Why it may matter
Itamar Medical may matter as a Health & BioTech entry with not currently an investable standalone company for Israeli technology research.
How an independent investor should read this
Not currently an investable standalone company. Read this profile as a starting point for independent verification, not as a recommendation or suitability assessment.
Evidence to verify
- Verify current status
- Verify technical claims
- Verify regulatory/export-control issues
Main investor questions
- Is this entry a benchmark, buyer, ecosystem node, acquired asset, or strategic reference rather than a live startup opportunity?
- What does this reference clarify about buyers, sector structure, public-market context, or strategic demand?
- Does the dual-use claim map to actual commercial and government/defense/resilience buyer evidence?
- What evidence would change the thesis or show that the profile is stale?
What not to infer
- Inclusion does not imply endorsement.
- Inclusion does not imply allocation availability or current fundraising.
- Scores do not indicate investment suitability or expected returns.
- Strategic importance does not automatically imply venture return potential.
Diligence questions
- What evidence verifies Itamar Medical's current customer traction, deployment status, and revenue concentration?
- Which technical claims are independently demonstrable today, and which remain roadmap or pilot-stage assertions?
- Where does the product create real defense, intelligence, critical-infrastructure, or emergency-response value beyond ordinary commercial adoption?
- What regulatory, procurement, and buyer-adoption constraints could slow deployment in strategic or government-adjacent markets?
- Is the company a live venture opportunity, a mature strategic reference, an acquired asset, or primarily a market-mapping entry?
Related sector
See the Health & BioTech sector page for market context, related subcategories, and other Israeli companies in this part of the database.
Related companies
Need a diligence readout?
Use the profile and related checklists as a starting point. If the decision needs more context, request a company screen, founder-call prep, diligence memo, or sector readout.